Six-year clinical evaluation of a copper-containing universal adhesive in non-carious cervical lesions: A split-mouth double-blind randomized clinical trial

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Who Took Part

The study group was 36 participants.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Two hundred and sixteen restorations (n = 54) were randomly placed in 36 participants with at least four NCCLs.

Restorations were evaluated at baseline and after 1, 3, 4, and 6 years using the FDI and USPHS criteria.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Groups included: ER-Cu (adhesive in etch-and-rinse strategy with CuNp), ER-Ct (etch-and-rinse without CuNp), SE-Cu (self-etch with CuNp), and SE-Ct (self-etch without CuNp).

What Was Measured

Topics PubMed links to this paper include Copper, Tooth Cervix, Dental Restoration, Permanent, Dental Restoration Failure, Dental Cements, Resin Cements and Metal Nanoparticles.

Author keywords: Clinical trial, Copper nanoparticles, Longevity, Non-carious cervical lesion and Universal adhesive system.

What This Means in Plain Language

The paper is a randomized and double-blind study of Copper (Supplement) in 36 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of dentistry), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.